We examined TSPY mRNA expression in tumours of different histological types and the seroreactivity against TSPY in HCC patients, suggesting that TSPY is a novel CT antigen capable of eliciting antibody response in HCC patients. This evidence concerns the gene TSPY1 and hepatocellular carcinoma.